Eli Lilly and Company
Q2 2022 Earnings Call
Aug 04, 2022, 10:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Welcome to the Lilly Q2 2022 earnings conference call. [Operator instructions] And as a reminder, your conference is being recorded. I would now like to turn the conference over to your host, Kevin Hern, vice president of investor relations. Please go ahead.
Kevin Hern -- Vice President, Investor Relations
Thank you. Good morning, everyone and thank you for joining us for Eli Lilly and Company's Q2 2022 earnings call. Apologies for the hour delay. We had some technical issues on AT&T side.
So thanks for your patience. I'm Kevin Hern, Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lilly's chair and CEO; and Anat Ashkenazi, chief financial officer; Dr. Dan Skovronsky, chief scientific and medical officer; Anne White, president of Lilly Neuroscience; Ilya Yuffa, president of Lilly International; Jake Van Naarden, CEO of Loxo at Lilly; Mike Mason, president of Lilly Diabetes; and Patrik Jonsson, president of Lilly Immunology and Lilly U.S.A.
We're also joined by Mike Springnether, Ken Zuluega, and Lauren Zerki of the investor relations team as well as Joe Fletcher, who will be taking over leadership of the IR team this month. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to several factors, including those listed on Slide 3. Additional information concerning factors that could cause actual results to differ materially is contained in our latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission.
The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions. As we transition to our prepared remarks, please note that our commentary will focus on non-GAAP financial measures. Now, I'll turn the call over to Dave.
Dave Ricks -- Chairman and Chief Executive Officer
Thanks a lot, Kevin. In Q2, we achieved a number of impactful pipeline milestones, including approval and launch of Mounjaro in the U.S., the FDA submission and acceptance of donanemab as well as pirtobrutinib and positive top line results for lebrikizumab and EU and Japan submissions for mirikizumab. This pipeline progress underscores the breadth and depth of our exciting long-term outlook. Perhaps the headline story for Lilly in the second quarter was the launch of Mounjaro in the U.S., where initial uptake has been strong.